Conversations on 
Twitter :
 |
|
|
|
@FierceBiotech: Celgene wraps $500M deal to partner with Sutro on next-gen ADCs. Article | Follow @FierceBiotech
@JohnCFierce: Hey, Actelion is (kind of) on a roll, with positive psoriasis data on PhII drug. Handily beats placebo. Article | Follow @JohnCFierce
@RyanMFierce: Interesting how Merck is using GE's experimental imaging agent in Alzheimer's trial for MK-8931. Does this add risk? Report | Follow @RyanMFierce
> New Haven, CT-based Trevi Therapeutics raised $10 million in Series A cash from the venture arm of TPG. The money is being earmarked for research work on T111, an oral extended-release opioid for the treatment of uremic pruritus. Uremic pruritus is a persistent and debilitating itching in patients on dialysis that has been linked to increased mortality. Release
> Arrowhead Research has inked a deal to collaborate with Shire ($SHPG) on the development of peptide-drug conjugates, with the potential to earn up to $32.8 million in milestones. Shire will also provide research support to Arrowhead. Release
> Lexington, MA-based Avaxia Biologics has raised $6.4 million to fund a first-in-human Phase 1b clinical trial of its oral anti-TNF antibody, AVX-470, for the treatment of ulcerative colitis. Existing investor Cherrystone Angels and new investor Golden Seeds led the round. Also participating in the round were existing investors Beacon Angels, Boston Harbor Angels, Launchpad Venture Group, Mass Medical Angels, and North Country Angels; new investors the Beta Fund, Granite State Angels, the Keiretsu Forum, and Maine Angels; and individual investors. Release
> Oncodesign and the Laboratory for Neurobiology and Gene Therapy at the Department of Neurosciences at the KU Leuven will collaborate with Ipsen on new compounds for Parkinson's disease. Release
Pharma News
@FiercePharma: A blow to Roche's Avastin hopes as NICE rejects it for ovarian cancer. News | Follow @FiercePharma
> NICE slaps down Roche's Avastin for ovarian cancer. Article
> Mylan chief jets to pop singer son's concerts on company aircraft. Story
@FierceMedDev: Quidel wins 510(k) for C. difficile molecular Dx. More | Follow @FierceMedDev
@MarkHFierce: More Dx funding--this time for Ortho Kinematics, a spine imaging Dx company--$2M Series B. Item | Follow @MarkHFierce
@DamianFierce: Medtronic posts more good renal denervation data, but it faces mounting competition from $BSX, $STJ. Story | Follow @DamianFierce
> St. Jude Medical enrolls first patient in cardiac stent imaging guidance trial. Article
> GE licenses Alzheimer's imaging agent to Merck. Report
> Disgraced ex-Home Diagnostics head avoids jail time. News
Pharma Manufacturing News
> Teva puts brakes on $300M Philly warehouse. News
> FDA's counterfeit drug probe sweeps up cancer doc. Article
Biotech Research News
> Acetylon's HDAC drug fights sickle cell disease, beta thalassemia in blood cell studies. Item
> Lifting the mood: Antidepressant could double as diabetes drug. Report
> Engineered viruses rebuild heartbeat. Article
> Rejected diabetes drug wakes up cell memories in Alzheimer's. News
> Gene therapy flips switch in sickle cell disease. Story
And Finally… Scientists at Sweden's Karolinska Institutet have devised plans for a new antibiotic that can fight TB and MRSA. Release